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SURGEON AT WORK
Right Portal Vein Ligation: A New Planned Two-Step
All-Surgical Approach for Complete Resection of
Primary Gastrointestinal Tumors with Multiple
Bilateral Liver Metastases
Reza Kianmanesh, MD, Olivier Farges, MD, PhD, Eddie K Abdalla, MD, Alain Sauvanet, MD,
Philippe Ruszniewski, MD, Jacques Belghiti, MD
Although complete resection of liver metastases remains
the only curative treatment for metastatic liver disease
from colorectal and endocrine gastrointestinal (GI) tu-
mors, only a small proportion of patients with liver me-
tastases are candidates for potentially curative surgery.1-20
Among these, 4% to 21% are found to have unresectable
disease because of multiplicity of the liver metastases, so
a very small proportion of such patients can be eligible
for complete resection.6,19,21-26 When the number and
distribution of liver metastases create the need for exten-
sive hepatic resection, the risk for postoperative liver
failure and morbidity related to the small size of the
remnant liver is increased.27-29 Additionally, substantial
operative risk results from the combination of extensive
hepatic resection with other major abdominal proce-
dures at a single operation, such as extended hepatec-
tomy with colorectal or pancreatic resections.1,30 On the
other hand, minor hepatic surgery, such as left liver
wedge resection, has been shown to be safe in combina-
tion with such extrahepatic procedures as those neces-
sary to treat many GI primary tumors.1,5,19,31,32
So, multistep, multimodality therapies including sur-
gery in several steps have been proposed and usually
require resection of the primary tumor in one step, fol-
lowed by extensive liver resection, with or without the
use of percutaneous ablative therapy or systemic
chemotherapy.1,10,23,33-35 Improved understanding of the
benefits of liver regeneration has led to other approaches
using intermediate steps between surgical
procedures.24,29,36-39 In patients expected to have a small
future liver remnant volume (FLR), most hepatic sur-
geons perform preoperative portal vein embolization
(PVE), mainly to avoid postoperative liver failure and to
decrease morbidity either after major hepatectomy in
patients with injured liver parenchyma (such as that
found in patients after extensive chemotherapy or in
patients with chronic liver disease) or when major hep-
atectomy is associated to major abdominal
procedures.24,29,36-39 But some investigators suggest that
in patients with bilobar liver metastases from colorectal
cancer, hypertrophy of the left liver induced by right
PVE might accelerate the progression of left-sided dis-
ease and therefore caution against the reckless use of
PVE in these cases.40,41
In order to use the benefits of diversion of portal flow
to the FLR, to avoid the risk of progression of liver
disease, and to minimize the risk and number of proce-
dures necessary to treat patients with GI tumors with
bilobar liver metastases, we developed a new planned
two-step, totally surgical approach to clear all primary
and metastatic disease. In the first step, the primary tu-
mor and all left-sided liver metastases (Couinaud S1 to
S4) are resected using straightforward resection tech-
niques. Simultaneously, right portal vein ligation
(RPVL) is performed to induce hypertrophy in the left
lobe, which has been cleared of all detectable disease.
Four to 8 weeks later, after hypertrophy of the disease-
free FLR, a second step consisting of a right or extended
right hepatectomy is planned to completely clear the
remaining right-sided liver metastases (Fig. 1).
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TECHNIQUE
Patients were carefully staged using endoscopy, spiral
CT with oral and intravenous contrast, and other spe-
cialized assessments (octreoscan, CT-portography)
when appropriate. Patients were eligible for the two-step
procedure when the metastatic disease was limited to the
liver (diffuse peritoneal disease excluded) and the pri-
mary tumor was intact.
In the first step, usually through a midline incision,
complete exploration of the abdomen was performed.
The liver was evaluated with bimanual palpation and
intraoperative ultrasonography. In the absence of perito-
neal carcinomatosis, the primary GI tumor was resected
using standard techniques. Then, all left-sided liver me-
tastases (S1 to S4) were removed by wedge resection(s),
generally without right liver mobilization. Next, a cho-
lecystectomy was usually performed to facilitate dissec-
tion of the right branch of the portal vein. Right portal
vein ligation (RPVL) was performed using nonabsorb-
able suture under ultrasound-Doppler control to ensure
that the entire right portal vein, and only the right portal
vein, was ligated. Postoperative complications were rig-
orously detailed prospectively.
Four to 8 weeks later, patients were restaged using tho-
racoabdominal CT with liver volumetry.42 The FLR was
defined as the liver that would remain after complete ana-
tomic resection of right-sided disease (usually S4 to S8
S1). The percent hypertrophy of the FLR was calculated by
CT volumetry using the following formula:
{% Hypertrophy  [(FLRvolume post-RPVL) 
(FLRvolume pre-RPVL)]  (FLRvolume pre-RPVL)]  100}
In the absence of tumor progression on restaging, the
second-step operation was performed through a separate
incision (J shaped), which provided optimum exposure of
Abbreviations and Acronyms
FLR  future liver remnant volume
GI  gastrointestinal
PVE  portal vein embolization
RPVL  right portal vein ligation
Figure 1. Description of the two-step all-surgical technique using right portal vein ligation for complete resection of
primary gastrointestinal tumors with multiple bilobar liver metastases.
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the liver and avoided the need for extensive lysis of adhe-
sions from the earlier procedure. The liver was again eval-
uated completely with bimanual palpation and intraoper-
ative ultrasonography with Doppler. Because the right liver
was not unnecessarily mobilized during the first procedure,
and because only necessary hilar dissection was performed
at the first procedure, adhesions were not extensive at the
second step. In the absence of peritoneal carcinomatosis, a
right hepatectomy (resection of S4 to S8) or right lobec-
tomy (S5 to S8 S1) was performed using standard tech-
niques39,43 to accomplish complete resection of remaining
hepatic metastases (Fig. 2).
RESULTS
Between 1996 and 2001, this two-step strategy was ap-
plied in 20 patients (11 women, 9 men, mean age
57 13 years). All patients had diffuse, bilobar liver
metastases and intact primary GI tumors. Tumor types
were colorectal adenocarcinoma in 12 patients and neu-
roendocrine tumors in 8 patients. Colorectal cancers in-
cluded four rectal and eight colon primaries. Neuroen-
docrine primaries were located in the ileum (one
patient), gastric antrum (one patient), and in the left
pancreas (six patients). The number of metastatic nod-
ules determined by preoperative CT (or CT portogra-
phy) and intraoperative ultrasound was confirmed by
pathologic analysis (mean 5.3 5 lesions in the right
liver [range 1 to 15 metastases] and 2.5 2 in the left
liver [range, 1 to 5 metastases]).
At the first-step procedure, 75% of the patients (15 of
20) underwent exploration through a midline incision.
All patients underwent complete macroscopic resection
of the primary and resection of one to five left-sided liver
metastases (S1 to S4). The RPVL was performed in all
Figure 2. (A and B) Preoperative CT scan of a patient with primary gastrointestinal tumor and multiple bilobar
neuroendocrine liver metastases. (C) Left liver segment hypertrophy seen in a CT scan 4 weeks after the first step
including the resection of both the primary tumor and left-sided liver metastases including those in segment 4,
associated with right portal vein ligation. (D) Postoperative CT scan 8 weeks after the second step including right
liver hepatectomy.
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patients without intraoperative incident. In 17 patients
(94%), cholecystectomy with minimal hilar dissection
was performed to facilitate RPVL. After the first step,
there were no major complications related to RPVL. A
single major complication occurred (bronchopulmo-
nary infection requiring antibiotic therapy [5%]). Nine
minor postoperative complications occurred (45%), in-
cluding urinary infection, asymptomatic pleural effu-
sion, wound infection, and superficial phlebitis. The
mean hospital stay after the first step was 12 days (range
6 to 20 days). First-step metastasectomies were margin-
negative except in one patient who had five left-sided
liver metastasectomies of colorectal origin (microscopic
margin was positive despite a grossly negative margin).
After a median interval of 6 weeks (range 4 to 8
weeks), the mean volume of the left liver (S2 S3 S4)
increased from 478 132 mL pre-RPVL (range 276 to
625 mL) to 632 184 mL post-RPVL (range 253 to
924 mL). The percent hypertrophy of the left liver (see
Technique section) was 32%  9%. The mean volume
of left lateral segments (S2  S3) increased from
273 85 mL (range 162 to 475 mL) preoperatively to
390 114 mL (215 to 634 mL) post RPVL, an increase
of 43% 13%. There were no tumor recurrences on the
left liver after RPVL and before the second step.
Fifteen patients (75%) underwent the second-step
operation. One patient died 1 month after the first step
after acute myocardial infarction and one refused the
second operation for personal reasons. Three patients
with colorectal primaries did not undergo the second-
step operation because restaging CT scan showed sub-
centimeter pulmonary metastases; one of these patients
had concomitant progression in size and number of his
multiple right-sided liver metastases. At the second-step
laparotomy, one patient was found to have diffuse peri-
toneal carcinomatosis that was not visible on restaging
CT scan before surgery. Finally, at the second step, 14 of
15 patients operated on (70% of the total population)
underwent the planned right liver resection, including
right hepatectomy (n 8), and right extended hepatec-
tomy to part or all of segment 4 (n 6). An elective
J-shaped incision was used in 10 patients (71%) and
bisubcostal incision in 4 patients (29%). There were no
major complications after the second-step operations in-
cluding no liver failure. The kinetics of liver function
changes after the first and the second steps did not de-
viate from the normal changes expected after hepatec-
tomy, and returned to baseline in the expected period
postresection.44,45 The rate of minor complications was
36% (asymptomatic pleural effusion detected by chest
radiography or CT, urinary infection, and minor wound
infection). The median duration of in-hospital stay after
the second step was 13 days (range 9 to 20 days). Among
patients who underwent the second-stage procedure, no
patient was left with gross residual disease and a com-
plete (R0) resection was accomplished in all except one
(R1).
DISCUSSION
Planned two-step surgery, including RPVL, is safe, ef-
fective, and enables complete removal of gross primary
GI tumors and synchronous diffuse liver metastases in
about 70% of patients with diffuse bilateral liver metas-
tases. Patients with colorectal cancer with synchronous
liver metastasis, particularly when liver metastases are
unresectable, have a poor prognosis with a 5-year sur-
vival from 0% to 8% and a median survival of just less
than a year.46,47 When primary tumor-related complica-
tions such as intestinal obstruction or bleeding are not
present, patients with primary GI tumors and appar-
ently unresectable liver metastases are often treated with
palliative intent without referral for specialized surgical
opinion. Indeed, in the setting of widely metastatic dis-
ease, resection of the primary tumor may be unwar-
ranted. Resection of an asymptomatic primary tumor
when hepatic metastatic disease is unresectable is gener-
ally not recommended except for intestinal endocrine
tumors, which are at higher risk for local complica-
tions.48 Even when resection of all of liver metastases is
technically possible, the patient’s overall performance
status, complexity of the surgical procedures, and the
volume of the planned future liver remnant size may
impact surgical decision making, especially when major
hepatic resection is considered simultaneously with ex-
trahepatic surgery.1,36,49,50
To overcome these problems, many multistep treat-
ments have been proposed including preoperative
chemotherapy.22-24,33,34,51-53 For example, after primary
tumor resection, systemic or hepatic-directed chemo-
therapy may be instituted for a period of time, followed
by reevaluation for potential second-stage resection of
down-staged liver disease.23 A more aggressive approach
includes resection of the primary tumor followed by
percutaneous ablative treatment or resection of unilat-
eral liver disease. Next, when indicated, intercurrent
portal vein embolization is performed in preparation for
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major resection of remaining disease a few weeks after
embolization.33,36,39 On the other end of the spectrum,
some patients will undergo no surgical treatment, with
chemotherapy only.
The concept of the reported technique was to maxi-
mize the proportion of patients who can safely undergo
potentially curative therapy of GI primary tumors with
diffuse, bilobar liver metastases. This new alternative
was developed to accomplish the following principal
goals: 1) to achieve complete (R0) resection of all tumors
with acceptable morbidity, 2) to resolve the problems
and potential problems related to the primary GI tumor
(primarily obstruction, bleeding, and perforation), and
3) to prepare patients for safe resection of their diffuse
liver metastatic disease (surgical cure) by initiating hy-
pertrophy of the disease-free left liver. Secondary goals
are important as well: 1) the primary procedure should
not interfere with standard intercurrent treatments, in-
cluding preoperative systemic chemotherapy or even
segmental PVE when indicated, and 2) the primary pro-
cedure should not create extensive adhesions (peritoneal
or hepatic hilar) that would greatly increase the difficulty
or complexity of the major hepatic resection planned for
the second step.
All these stated goals were accomplished using the
described technique. The potential additive morbidity
of major abdominal surgery and simultaneous major
liver surgery was avoided because primary tumor resec-
tion was combined with straightforward liver resection,
and the major hepatic resection was performed as a sep-
arate procedure. The liver hypertrophy induced by
RPVL was effective, indeed similar to that seen after
PVE despite the theoretic risk for recanalization.54
RPVL was not associated with morbidity, and the risk
for disease progression in the left liver was avoided. Be-
cause there is no contraindication to systemic chemo-
therapy after the first step, even those who were found to
have progressive disease before or at the time of the sec-
ond laparotomy remained candidates for traditional ad-
juvant therapy. Those with progression were likely
spared the risk of major hepatic resection as a result of
the discovery of previously unidentifiable disease found
during the window of observation between steps.
Importantly, because major hepatic resection is not
combined with primary tumor resection, the attendant
risks of combined major resection with extrahepatic ab-
dominal surgery are avoided and the goal of minimum
morbidity is better achieved. Indeed, an essential part of
the first-stage procedure is to prepare for the second step.
At each part of the procedure, attention is directed to-
ward safe, complete resection of the primary or left liver
disease without unnecessary dissection or mobilization
that could impact the difficulty of the second step. In a
majority of the cases, different incisions are possible to
further minimize adhesion-related difficulties at the sec-
ond step. Excessive dissection of the porta hepatis is
always avoided to facilitate redissection at the second
procedure. We believe that the avoidance of cholecystec-
tomy when possible could facilitate dissection at the sec-
ond procedure. But in patients with neuroendocrine dif-
fuse liver metastases, if the planned second step is
considered unachievable, we suggest performing a cho-
lecystectomy without RPVL because further intraarte-
rial chemoembolization might be indicated.55,56 Uni-
form use of intraoperative ultrasonography ensures
accurate staging and complete resection of the left-sided
metastases during the period of hypertrophy of the left
liver.57 Finally, although the dissociation of primary GI
tumor and major liver resection may by itself reduce the
postoperative morbidity, we believe that apart from
volumetric considerations, a large proportion of patients
with liver metastases may have injured liver parenchyma
as a result of a long period of systemic or intraarterial
chemotherapy, so are likely to benefit from hypertophy
induced by portal vein ligation before major liver
resection.36
In conclusion, an oncologic, all-surgical approach to
patients with gastrointestinal primary tumors and bilo-
bar liver metastases is feasible. Resection of the primary
GI tumor and all left-sided liver metastases with RPVL
at the first step provides left liver hypertrophy without
the risk for progression of disease in the FLR in prepa-
ration for the second, curative major liver resection to
remove the remaining right-sided liver disease. In dis-
tinction to other techniques, liver hypertrophy induced
after portal vein ligation is initiated in a liver cleared of
metastatic disease, which limits the risk of tumor pro-
gression during the observation period. Other therapies,
including portal vein embolization and systemic chemo-
therapy, could be administered if desired in selected
cases after the first step. An observation period is neces-
sary for recovery from the first-stage procedure, which
enables better selection of patients for major hepatic
resection at the second step. This planned, two-step sur-
gical approach using portal vein ligation may be consid-
ered in patients who might previously have been consid-
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ered only for palliative or supportive treatment because
of the presence of primary GI tumors with apparently
“unresectable” diffuse, bilobar liver metastases. Further
study is necessary to assess the potential impact of this
strategy on longterm survival in patients with intact pri-
mary GI tumors and synchronous diffuse bilobar liver
metastases.
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